Methylation of CIITA promoter IV causes loss of HLA-II inducibility by IFN-γ in promyelocytic cells

International Immunology

Volumn 20, Issue 11, 2008, Pages 1457-1466

  De Lerma Barbaro, Andrea ^a   De Ambrosis, Alessandro ^b   Banelli, Barbara ^b   Pira, Giuseppina Li ^c   Aresu, Ottavia ^b   Romani, Massimo ^b   Ferrini, Silvano ^b   Accolla, Roberto S ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c Advanced Biotechnology Center   (Italy)

Author keywords

5 azacytidine; Gene regulation; MHC class II; Transcription factors

Indexed keywords

GAMMA INTERFERON; HLA ANTIGEN CLASS 2; HLA DR ANTIGEN; PROTEIN CIITA; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; CELL LINEAGE; CELL STRAIN U937; CONTROLLED STUDY; CYTOMEGALOVIRUS; EPIGENETICS; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOREGULATION; MONOCYTE; PRIORITY JOURNAL; PROMOTER REGION; PROMYELOCYTE; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METHYLATION; PROTEIN PROCESSING; PROTEIN VARIANT; SIGNAL TRANSDUCTION;

ANTIGEN PRESENTATION; AZACITIDINE; DNA METHYLATION; GRANULOCYTE PRECURSOR CELLS; HLA-DR ANTIGENS; HUMANS; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; NUCLEAR PROTEINS; PROMOTER REGIONS, GENETIC; TRANS-ACTIVATORS; TRANSCRIPTIONAL ACTIVATION; U937 CELLS;

EID: 54949098209     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxn103     Document Type: Article

References (36)

1. Germain, R. N. and Margulies, D. H. 1993. The biochemistry and cell biology of antigen processing and presentation. Annu. Rev. Immunol. 11:403.
2. Reith, W. and Mach, B. 2001. The bare lymphocyte syndrome and the regulation of MHC expression. Annu. Rev. Immunol. 19:331.
3. Accolla, R. S., Jotterand-Bellomo, M., Scarpellino, L., Maffei, A., Carra, G. and Guardiola, J. 1986. aIr-1, a newly found locus on mouse chromosome 16 encoding a trans-acting activator factor for MHC class II gene expression. J. Exp. Med. 164:369.
4. Muhlethaler-Mottet, A., Otten, L. A., Steimle, V. and Mach, B. 1997. Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA. EMBO J. 16:2851.
5. Schroder, K., Hertzog, P. J., Ravasi, T. and Hume, D. A. 2004. Interferon-gamma: An overview of signals, mechanisms and functions. J. Leukoc. Biol. 75:163.
6. Muhlethaler-Mottet, A., Di Bernardino, W., Otten, L. A. and Mach, B. 1998. Activation of the MHC class II transactivator CIITA by interferon-gamma requires cooperative interaction between Stat1 and USF-1. Immunity 8:157.
7. Lovig, T., Andersen, S. N., Thorstensen, L. et al. 2002. Strong HLA-DR expression in microsatellite stable carcinomas of the large bowel is associated with good prognosis. Br. J. Cancer 87:756.
8. Sheen-Chen, S. M., Chou, F. F., Eng, H. L. and Chen, W. J. 1994. An evaluation of the prognostic significance of HLA-DR expression in axillary-node-negative breast cancer. Surgery 116:510.
9. Matsushita, N., Ghazizadeh, M., Konishi, H. and Araki, T. 2003. Association of ovarian tumor epithelium coexpressing HLA-DR and CA-125 antigens with tumor infiltrating cytotoxic T lymphocytes. J. Nippon Med. Sch. 70:40.
10. Rimsza, L. M., Roberts, R. A., Miller, T. P. et al. 2004. Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions. Blood 103:4251.
11. van Duinen, S. G., Ruiter, D. J., Broecker, E. B. et al. 1988. Level of HLA antigens in locoregional metastases and clinical course of the disease in patients with melanoma. Cancer Res. 48:1019.
12. Armstrong, T., Clements, V., Matin, B., Ting, J. and Ostrand-Rosenberg, S. 1997. Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity. Proc. Natl Acad. Sci. USA 94:6886.
13. Meazza, R., Comes, A., Orengo, A. M., Ferrini, S. and Accolla, R. S. 2003. Tumor rejection by gene transfer of the MHC class II transactivator in murine mammary adenocarcinoma cells. Eur. J. Immunol. 33:1183.
14. Mortara, L., Castellani, P., Meazza, R. et al. 2006. CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory. Clin. Cancer Res. 12:3435.
15. Croce, M., De Ambrosis, A., Corrias, M. V. et al. 2003. Different levels of control prevent interferon-gamma-inducible HLA-class II expression in human neuroblastoma cells. Oncogene 22:7848.
16. Satoh, A., Toyota, M., Ikeda, H. et al. 2004. Epigenetic inactivation of class II transactivator (CIITA) is associated with the absence of interferon-gamma-induced HLA-DR expression in colorectal and gastric cancer cells. Oncogene 23:8876.
17. Wright, K. L. and Ting, J. P. 2006. Epigenetic regulation of MHC-II and CIITA genes. Trends Immunol. 27:405.
18. Tsuchiya, S., Yamabe, M., Yamaguci, Y., Kabayashi, Y., Konno, T. and Tada, K. 1980. Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int. J. Cancer 26:171.
19. De Lerma Barbaro, A., Tosi, G., Valle, M. T. et al. 1999. Distinct regulation of HLA class II and class I cell surface expression in the THP-1 macrophage cell line after bacterial phagocytosis. Eur. J. Immunol. 29:499.
20. Masters, J. R., Thomson, J. A., Dely-Burns, B. et al. 2001. Short tandem repeat profiling provides an international reference standard for human cell lines. Proc. Natl Acad. Sci. USA 98:8012.
21. Sallusto, F. and Lanzavecchia, A. 1994. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med. 179:1109.
22. De Lerma Barbaro, A., Procopio, F. A., Mortara, L., Tosi, G. and Accolla, R. S. 2005. The MHC class II transactivator (CIITA) mRNA stability is critical for the HLA class II gene expression in myelomonocytic cells. Eur. J. Immunol. 35:603.
23. De Ambrosis, A., Casciano, I., Croce, M. et al. 2007. An interferon-sensitive response element is involved in constitutive caspase-8 gene expression in neuroblastoma cells. Int. J. Cancer 120:39.
24. Hornell, T. M., Beresford, G. W., Bushey, A., Boss, J. M. and Mellins, E. D. 2003. Regulation of the class II MHC pathway in primary human monocytes by granulocyte-macrophage colony-stimulating factor. J. Immunol. 171:2374.
25. Holtz, R., Choi, J. C., Petroff, M. G., Piskurich, J. F. and Murphy, S. P. 2003. Class II transactivator (CIITA) promoter methylation does not correlate with silencing of CIITA transcription in trophoblasts. Biol. Reprod. 69:915.
26. Dupont, J. M., Tost, J., Jammes, H. and Gut, I. G. 2004. De novo quantitative bisulfite sequencing using the pyrosequencing technology. Anal. Biochem. 333:119.
27. Frommer, M., McDonald, L. E., Millar, D. S. et al. 1992. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc. Natl Acad. Sci. USA 89:1827.
28. Valle, M. T., Megiovanni, A. M., Merlo, A. et al. 2001. Epitope focus, clonal composition and Th1 phenotype of the human CD4 response to the secretory mycobacterial antigen Ag85. Clin. Exp. Immunol. 123:226.
29. Cameron, E. E., Bachman, K. E., Myohanen, S., Herman, J. G. and Baylin, S. 1999. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet. 21:103.
30. Jayaram, Y., Buckle, A. M. and Hogg, N. 1989. The Fc receptor, FcRI, and other activation molecules on human mononuclear phagocytes after treatment with interferon-gamma. Clin. Exp. Immunol. 75:414.
31. Morris, A. C., Spangler, W. E. and Boss, J. M. 2000. Methylation of class II trans-activator promoter IV: A novel mechanism of MHC class II gene control. J. Immunol. 164:4143.
32. van den Elsen, P. J., van der Stoep, N., Datema, G. and Vietor, H. E. 2001. Transcriptional control of MHC genes in fetal trophoblast cells. J. Reprod. Immunol. 52:129.
33. Morimoto, Y., Toyota, M., Satoh, A. et al. 2004. Inactivation of class II transactivator by DNA methylation and histone deacetylation associated with absence of HLA-DR induction by interferon-gamma in haematopoietic tumour cells. Br. J. Cancer 90:844.
34. Antequera, F., Boyes, J. and Bird, A. 1990. High levels of de novo methylation and altered chromatin structure at CpG islands in cell lines. Cell 62:503.
35. Jones, P., Wolkowicz, M. J., Rideout, W. M. et al. 1990. De novo methylation of the MyoD1 CpG island during the establishment of immortal cell lines. Proc. Natl Acad. Sci. USA 87:6117.
36. Sigalotti, L., Coral, S., Fratta, E. et al. 2005. Epigenetic modulation of solid tumors as a novel approach for cancer immunotherapy. Semin. Oncol. 32:473.